Keratoacanthoma - Keratoakantóm
☆ Vo výsledkoch Stiftung Warentest z Nemecka za rok 2022 bola spokojnosť spotrebiteľov s ModelDerm len o niečo nižšia ako s platenými telemedicínskymi konzultáciami.
Typické Keratoakantóm (Keratoacanthoma)
References
Keratoacanthoma (KA) je častý kožný nádor známy svojim rýchlym rastom a potenciálom samostatne regredovať. Typicky sa vyskytuje u starších mužov svetlej pleti s anamnézou poškodenia slnkom. Zatiaľ čo chirurgické odstránenie pomocou excízie alebo Mohsovej mikrografickej chirurgie je zvyčajnou liečbou, existujú rôzne ďalšie možnosti liečby.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) je nádor nízkeho stupňa, ktorý začína v určitých žľazách v koži a pod mikroskopom vyzerá podobne ako squamous cell carcinoma (SCC) . Prebieha diskusia o tom, či by KA mala byť klasifikovaná ako forma invazívneho SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) je druhým najčastejším typom rakoviny u ľudí, najmä u starších jedincov. Chirurgický zákrok sa zvyčajne používa na liečbu cSCC, ale pre niektorých pacientov, ktorí nemôžu podstúpiť operáciu alebo sa rozhodnú nie, možno zvážiť iné možnosti, ako je intralezionálna liečba. Použili sa tradičné intralezionálne liečby (methotrexate or 5-fluorouracil) , ale stále prebieha výskum nových prístupov, ako je intralezionálna imunoterapia a onkolytická viroterapia. Tu sa pozrieme na rôzne intralezionálne liečby cSCC, od klasických metód až po špičkové stratégie.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Pod mikroskopom keratoakantóm (keratoacanthoma) veľmi pripomína spinocelulárny karcinóm. Zatiaľ čo niektorí patológovia klasifikujú keratoakantóm (keratoacanthoma) ako odlišnú entitu a nie ako malignitu, asi 6 % klinických a histologických keratoakantóm (keratoacanthoma) sa rozvinie do invazívnych a agresívnych skvamocelulárnych karcinómov.
○ Diagnostika a liečba
#Dermoscopy
#Skin biopsy